Al­ny­lam’s longer-term RNAi treat­ment low­ers blood pres­sure in mid-stage study

One to two dos­es of an RNA in­ter­fer­ence treat­ment de­vel­oped by Al­ny­lam Phar­ma­ceu­ti­cals re­duced blood pres­sure for six months in a mid-stage clin­i­cal tri­al, ac­cord­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.